Related Experiment Videos
[Does clinical research provide any "direct individual benefit"?].
1Service de réanimation médicale, Hôpital Henri-Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. francois.lemaire@hmn.ap-hop-paris.fr
Medecine Sciences : M/S
|March 5, 2004
Summary
France revised its clinical research law to align with European directives. The key change removes the distinction between research with and without direct individual benefit, harmonizing laws and updating regulations.
Area of Science:
- Medical Law and Ethics
- Clinical Research Regulation
- European Union Directives
Context:
- The European Commission and Parliament issued a clinical research directive (2001/20/CE) in April 2001.
- National laws were required to incorporate the directive's provisions by May 2004.
- The existing French law 'loi Huriet' (1988) needed revision to comply.
Purpose:
- To harmonize French clinical research legislation with European Union standards.
- To address the need to revise the 'loi Huriet' in line with the 2001/20/CE directive.
- To eliminate a French legal specificity regarding 'direct individual benefit' in clinical research.
Summary:
- The French Parliament voted in October 2003 to amend the 'loi Huriet'.
- A significant modification involved suppressing the distinction between research with and without 'direct individual benefit'.
- This change aligns French law with the European directive's emphasis on the risk/benefit ratio.
Impact:
- Ensures French clinical research law is consistent with broader European regulations.
- Removes a contested legal distinction that had been subject to criticism.
- Facilitates smoother integration of clinical research practices across member states.